Lifecore Biomedical Inc. (LFCR) Stock Forecast & Price Target
Lifecore Biomedical Inc. · NASDAQ
$4.32-0.01 (-0.22%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Lifecore Biomedical Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $6.50 to $6.50, so the covering firms are broadly aligned. The average target of $6.50 sits 50% above the current $4.32. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.22 next quarter toward $-0.98 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Lifecore Biomedical Inc.
As of Jul, 1 of 2 firms rate LFCR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LFCR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.22
Range $-0.29 – $-0.11 · 4 analysts
Next period, 4 analysts expect Lifecore Biomedical Inc. to earn $-0.22 a share (range $-0.29 – $-0.11), versus — a year earlier. Full-year consensus is $-1.04, growing to $-0.98 the year after.
REVENUE · NEXT QUARTER
$33.3M
Range $30.5M – $38.1M · 4 analysts
Revenue is expected to reach $33.3M (range $30.5M – $38.1M). Full-year consensus is $122.2M, rising to $130.2M next year.
Top analysts covering Lifecore Biomedical Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LFCR.
#1
Paul Knight
Keybanc · Rank #296
Hold
No targeton LFCR
Overall win rate
32%
+ Follow
#2
Michael Petusky
Barrington Research · Rank #322
Buy
$6.50+50.4% to target
Overall win rate
29%
+ Follow
LFCR stock forecast FAQ
What is LFCR's average 12-month price target?+
The 1 analysts with a live target average $6.50 for Lifecore Biomedical Inc. over the next 12 months, ranging from a $6.50 high to a $6.50 low.
Is LFCR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover LFCR?+
2 analysts have an active rating on Lifecore Biomedical Inc., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering LFCR?+
Among analysts who currently cover LFCR, Paul Knight of Keybanc has the strongest overall Quantellect track record (Rank #296). Their current call is Hold.
What is Lifecore Biomedical Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.22 per share (range $-0.29 – $-0.11) across 4 analysts. Full-year EPS is projected at $-1.04, rising to $-0.98 the following year.
How much revenue is Lifecore Biomedical Inc. expected to report next quarter?+
Consensus revenue is $33.3M (range $30.5M – $38.1M). Full-year revenue is projected at $122.2M, growing to $130.2M next year.
Have analysts been upgrading or downgrading LFCR lately?+
As of Jul, 1 of 2 firms rate LFCR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LFCR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
